Entero Therapeutics signs LOI to license clinical trial compliance platform from DataVault Holdings

GridAI Technologies Corp.

Binding LOI for exclusive worldwide license to QOLPOM and FotoDigm clinical trial software from DataVault Holdings.
Consideration: $250,000 in convertible preferred shares priced at 180% of 5-day VWAP plus single-digit royalties on net sales.
Deal contingent on Entero securing at least $500,000 strategic investment; target up to $3M.
License intended to support Entero's planned Phase 3 latiglutenase trial for celiac disease and other GI indications.
Right of first refusal to fully acquire the assets; closing targeted by end of September 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.